About
Vivosim Labs, Inc. (NASDAQ:VIVS) — investor relations, events, news, and company updates on 6ix.
Latest News
Yesterday
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
Apr 1 2026
VivoSim Announces Pricing of up to a $4 Million Public Offering
Mar 24 2026
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
Mar 3 2026
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
Feb 11 2026
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
Financials
Revenue
$142 K
Market Cap
$4.43 M
P/E Ratio
0.87
EPS
1.76
Translate